{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:04:21Z","timestamp":1761919461822},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T00:00:00Z","timestamp":1310947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Highly active antiretroviral therapy (HAART) of HIV+ patients with haemophilia poses specific questions on safety and effectiveness because of long\u2010lasting HIV infection, multidrug resistance, concomitant chronic liver disease and bleeding risk. Raltegravir belongs to a new class of drugs that inhibits HIV integrase and is known to have a good effectiveness and safety profile. The aim of this study was to evaluate safety and effectiveness of HAART with raltegravir in patients with haemophilia. HIV+ patients with haemophilia treated with raltegravir for \u22656\u2003months were included in this retrospective study. Safety criteria were: occurrence of any adverse event, unexpected blood test abnormalities and increased consumption of coagulation factors. Effectiveness criteria were: no disease progression, viral load &lt;40 HIV\u2010RNA copies\u2003mL<jats:sup>\u22121<\/jats:sup> and increased or stable CD3+ CD4+ cell count above 200\u2003cells\u2003cmm<jats:sup>\u22121<\/jats:sup>. Seven patients with HCV co\u2010infection underwent treatment with raltegravir for a median of 20\u2003months (min\u2013max: 7\u201330). Before starting treatment with raltegravir, three patients had CD3+ CD4+ cell counts &lt;200\u2003cells\u2003cmm<jats:sup>\u22121<\/jats:sup>. The median viral load was 7547\u2003copies\u2003mL<jats:sup>\u22121<\/jats:sup> (min\u2013max: &lt;40\u201337\u2003807). During treatment, no new sign of disease progression was observed. All patients showed suppression of viral replication (&lt;40 HIV\u2010RNA copies\u2003mL<jats:sup>\u22121<\/jats:sup>). CD3+ CD4+ cell counts showed a median increase of 152\u2003cells\u2003cmm<jats:sup>\u22121<\/jats:sup> (min\u2013max: 40\u2013525). Two patients suffered from peripheral neuropathy, which was deemed as possibly associated with raltegravir. There was no evidence of increased bleeding frequency, modification of bleeding sites and lack of response to replacement therapy. Raltegravir\u2010based HAART appeared to be effective and generally well\u2010tolerated in patients with haemophilia, and it might represent a useful option in these patients.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2011.02610.x","type":"journal-article","created":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T11:32:18Z","timestamp":1310988738000},"page":"108-111","source":"Crossref","is-referenced-by-count":6,"title":["Safety and effectiveness of raltegravir in patients with haemophilia and anti\u2010HIV multidrug resistance"],"prefix":"10.1111","volume":"18","author":[{"given":"L.","family":"MANGIAFICO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"PERJA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"FUSCO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"RIVA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"MAGO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"GRINGERI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02919084"},{"key":"e_1_2_7_3_2","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis N","year":"2003","journal-title":"AIDS Rev"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01935.x"},{"key":"e_1_2_7_5_2","unstructured":"European Medicines Agency (EMA).Summary of the European Public Assessment Report (EPAR) for Isentress Merck Sharp & Dohme Ltd. Hertfordshire UK. Last update 12\/05\/2010. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Summary_for_the_public\/human\/000860\/WC500037406.pdf. Accessed July 4 2011."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq350"},{"key":"e_1_2_7_8_2","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00154.x"},{"key":"e_1_2_7_10_2","unstructured":"FDA \u2013 Food and Drug Administration.Traditional Approval of Isentress (Raltegravir). Page last updated: 07\/01\/2009. Available athttp:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm121529.htm. Accessed March 7 2011."},{"key":"e_1_2_7_11_2","first-page":"187","article-title":"Clinical pharmacology profile of raltegravir, an HIV\u20101 integrase strand transfer inhibitor","volume":"30","author":"Brainard DM","year":"2010","journal-title":"Clin Physiol Funct Imaging"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969080-00007"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.10.012"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2011.02610.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2011.02610.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:22:29Z","timestamp":1697368949000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2011.02610.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1111\/j.1365-2516.2011.02610.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02610.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,18]]}}}